哥伦比亚胃癌药物市场，按类型（腺癌、胃肠道间质瘤、类癌瘤、淋巴瘤等）、分期（III 期、II 期、IV 期、I 期等）、治疗（化疗、靶向治疗、免疫检查点抑制剂等）、给药途径（肠胃外、口服等）、最终用户（医院、专科诊所、研究和学术机构等）、分销渠道（医院药房、零售药房等）划分的行业趋势和预测（至 2029 年）
市场分析和见解哥伦比亚胃癌药物市场
哥伦比亚胃癌药物市场预计将在2022至2029年的预测期间取得显著增长。 数据桥市场研究分析认为,在2022至2029年的预测期间,CAGR增长8.5%,预计到2029年将达到4,773万美元. 肠胃病例增多肿瘤, 淋巴瘤并增加了对药物和治疗的需求,预计将推动胃病的增长。癌症毒品市场。
胃脏癌症是恶性(癌症)细胞在胃的内脏中形成的一种疾病. 年龄、饮食和胃病会影响胃癌的发展。 胃癌的症状包括消化不良和胃部不适或疼痛. 胃癌呈多年缓慢发展趋势. 在真正的癌症发作之前,先天性的变化经常会发生在癌症完全发作之前的胃内膜(mucosa). 这些早期的改变很少引起症状,所以经常会不被发现. 癌症在胃的不同部位的发育可引起不同的症状并往往产生不同的结果. 它的位置也会影响治疗方案.
胃癌发病率的上升和保健支出的增加预计将推动整个哥伦比亚的市场增长。
哥伦比亚胃癌药物 市场范围和市场规模
哥伦比亚胃癌药物市场按类型、阶段、治疗、管理路线、最终用户和分销渠道进行分化。 不同部门之间的增长有助于你分析特殊的增长领域和接近市场的战略,并确定你的核心应用领域以及目标市场的差异。
- 根据类型,市场被分化为腺癌,淋巴瘤,胃肠分泌的分泌腺瘤,鲤鱼瘤等. 2022年,由于为哥伦比亚胃癌治疗市场生产药物的研究开发过度,预计该地的腺癌部分将占据主导地位.
- 以阶段为基础,将市场分为一,二,三,四等阶段. 2022年,由于哥伦比亚胃癌药物市场迅速蔓延,而胃癌的诊断延迟导致癌症的阶段,因此第三阶段将占据主导地位。
- 以治疗为基础,将市场分为化疗,定点疗法,免疫疗法等. 2022年,由于越来越多地采用其他治疗方法的化学疗法,化疗部分预计将主导哥伦比亚胃癌治疗市场.
- 根据管理路线,市场分为口述和亲述两种. 2022年,由于母体剂量的生物利用率高,加上母体胃癌市场上的大多数产品,母体部分预计将主导哥伦比亚胃癌药物市场。
- 以最终用户为基础,将市场分为专科诊所、医院、研究和学术机构等。 2022年,预计医院部分将主导哥伦比亚胃癌药物市场,因为哥伦比亚的医院正在建立综合癌症护理中心,是哥伦比亚保健的主要来源。
- 根据分销渠道,市场被分割成零售药店,医院药店等. 2022年,由于胃癌患者一般倾向于医院提供更好的治疗,预计医院药房分科疾病分科将主导哥伦比亚胃癌药物市场.
主要市场参与者为促进市场增长提高对胃癌的认识而开展越来越多的战略活动
哥伦比亚胃癌药物市场也向你们提供了各国具体市场增长的详细市场分析。 此外,报告还详细介绍了市场参与者的战略及其地域存在。 现有2020年至2029年期间的数据。
竞争性景观和哥伦比亚胃癌药物市场
哥伦比亚胃癌药物市场竞争情况提供了竞争者的详情。 详细情况包括:公司概况,公司财务,创收,市场潜力,研发投资,新市场举措,生产地和设施,公司优势和弱点,产品推出,产品试验管线,产品审批,专利,产品宽度和广度,应用优势,技术命脉曲线等. 上述数据点仅与哥伦比亚胃癌药物市场有关的公司重点有关
在哥伦比亚胃癌药物市场交易的一些主要公司有:Bayer AG、Novartis AG、Pfize Inc.、Celltrion保健公司、Ltd.、F.Hoffmann-La Roche Ltd、Merck KGaA、Teva制药工业有限公司、Sanofi、AstraZeneca、Viatris Inc.、Bristol-Myers Squibb公司、Concord生物技术公司和GlaxoSmithKline plc等。 DBMR分析师了解竞争优势,为每个竞争者分别提供竞争分析.
许多合同和协议也是由世界各地的公司发起的,它们正在进一步加快哥伦比亚胃癌药物市场的增长。
比如说,
- 2018年4月,Celltrion Healthcare宣布,他们扩大了与制药商Mundipharma的伙伴关系,在哥伦比亚许可,销售并分销其特鲁克西玛癌症治疗药物.
- 2020年11月,辉瑞股份有限公司宣布其名为"Upjohn"的分公司与Mylan N.V.合并,并组建了一家名为"Viatris"的新公司. 公司业务分工与Mylan N.V.的这种组合增加了其产品组合,导致其产品在市场上的需求增加.
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF COLOMBIA GASTRIC CANCER DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 COLOMBIA GASTRIC CANCER DRUGS MARKET: REGULATORY SCENARIO
6 SUMMARY WRITE UP (COLOMBIA)
6.1 OVERVIEW
7 PIPELINE ANALYSIS FOR COLOMBIA GASTRIC CANCER DRUGS MARKET
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 GROWING GASTRIC CANCER BURDEN WORLDWIDE
8.1.2 GROWING GERIATRIC POPULATION
8.1.3 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANISATIONS
8.1.4 RISING NUMBER OF PRODUCT APPROVALS
8.2 RESTRAINTS
8.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH GASTRIC CANCER TREATMENT DRUGS
8.2.2 LACK OF EARLY DETECTION OF GASTRIC CANCER
8.3 OPPORTUNITIES
8.3.1 RECENT ADVANCEMENTS IN GASTRIC CANCER TREATMENT
8.3.2 ADOPTION OF AUTOMATED SYSTEMS
8.3.3 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.4 CHALLENGES
8.4.1 CHALLENGE RELATED TO COLOMBIAN HEALTHCARE
8.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES
9 IMPACT OF COVID-19 PANDEMIC ON COLOMBIA GASTRIC CANCER DRUGS MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TYPE
10.1 OVERVIEW
10.2 ADENOCARCINOMA
10.3 GASTROINTESTINAL STROMAL TUMOR
10.4 CARCINOID TUMOR
10.5 LYMPHOMA
10.6 OTHERS
11 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY STAGES
11.1 OVERVIEW
11.2 STAGE III
11.3 STAGE II
11.4 STAGE IV
11.5 STAGE I
11.6 OTHERS
12 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TREATMENT
12.1 OVERVIEW
12.2 CHEMOTHERAPY
12.2.1 CISPLATIN
12.2.2 OXALIPLATIN
12.2.3 FLUOROURACIL
12.2.4 DOCETAXEL
12.2.5 CAPECITABINE
12.2.6 CARBOPLATIN
12.2.7 EPIRUBICIN
12.2.8 PACLITAXEL
12.2.9 IRINOTECAN
12.2.10 OTHERS
12.3 TARGETED THERAPY
12.3.1 MONOCLONAL ANTIBODY THERAPY
12.3.1.1 TRASTUZUMAB (HERCEPTIN)
12.3.1.2 RAMUCIRUMAB
12.3.2 MULTIKINASE INHIBITORS
12.3.2.1 SUNITINIB
12.3.2.2 REGORAFENIB
12.4 IMMUNE CHECKPOINT INHIBITORS
12.5 OTHERS
13 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 PARENTERAL
13.2.1 INTRAVENOUS
13.2.2 SUBCUTANEOUS
13.2.3 OTHERS
13.3 ORAL
13.3.1 TABLET
13.3.2 CAPSULE
13.3.3 OTHERS
13.4 OTHERS
13.5 OVERVIEW
13.6 HOSPITALS
13.7 SPECIALITY CLINICS
13.8 RESEARCH & ACADEMIC INSTITUTES
13.9 OTHERS
14 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 OTHERS
15 COLOMBIA GASTRIC CANCER DRUGS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 F.HOFFMAN-LA ROCHE
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.1.4.1 AGREEMENT
17.2 MERCK KGAA (A SUBSIDIARY OF MERCK & CO., INC.)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVELOPMENTS
17.2.4.1 PRODUCT APPROVAL
17.2.4.2 EVENTS
17.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.3.4.1 COLLABORATION
17.4 SANOFI
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.4.4.1 ACQUISITION
17.5 ASTRAZENECA
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.5.4.1 PRODUCT APPROVAL
17.6 BAYER AG
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.6.4.1 COLLABORATION
17.7 BRISTOL-MYERS SQUIBB COMPANY
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.7.4.1 PRODUCT APPROVAL
17.8 CELLTRION HEALTHCARE CO., LTD.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.8.4.1 PRODUCT APPROVAL
17.9 CONCORD BIOTECH.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 GLAXOSMITHKLINE PLC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.10.4.1 PRODUCT APPROVAL
17.11 NOVARTIS AG
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.11.4.1 PRODUCT LAUNCH
17.12 PFIZER INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.12.4.1 MERGER
17.12.4.2 COLLABORATION
17.13 VIATRIS INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 3 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 4 COLOMBIA CHEMOTHERAPY IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 5 COLOMBIA TARGETED THERAPY IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 6 COLOMBIA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 7 COLOMBIA MULTIKINASE INHIBITORS IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 8 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 9 COLOMBIA PARENTRAL IN GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 10 COLOMBIA ORAL IN GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 11 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 12 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 COLOMBIA GASTRIC CANCER DRUGS MARKET: SEGMENTATION
FIGURE 2 COLOMBIA GASTRIC CANCER DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 COLOMBIA GASTRIC CANCER DRUGS MARKET: DROC ANALYSIS
FIGURE 4 COLOMBIA GASTRIC CANCER DRUGS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 COLOMBIA GASTRIC CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 COLOMBIA GASTRIC CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 COLOMBIA GASTRIC CANCER DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 8 COLOMBIA GASTRIC CANCER DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 COLOMBIA GASTRIC CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 COLOMBIA GASTRIC CANCER DRUGS MARKET: END USER OVERAGE GRID
FIGURE 11 COLOMBIA GASTRIC CANCER DRUGS MARKET: SEGMENTATION
FIGURE 12 INCREASING IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA AND ADENOCARCINOMA AND HIGH PREVALENCE OF OBESITY ARE EXPECTED TO DRIVE THE COLOMBIA GASTRIC CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE COLOMBIA GASTRIC CANCER DRUGS MARKET IN 2022 & 2029
FIGURE 14 REGULATORY PROCESS OF DRUGS AND BIOLOGICS APPROVAL IN COLOMBIA
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF COLOMBIA GASTRIC CANCER DRUGS MARKET
FIGURE 16 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TYPE, 2021
FIGURE 17 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 18 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY STAGES, 2021
FIGURE 21 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY STAGES, 2020-2029 (USD MILLION)
FIGURE 22 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY STAGES, CAGR (2022-2029)
FIGURE 23 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY STAGES, LIFELINE CURVE
FIGURE 24 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TREATMENT, 2021
FIGURE 25 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TREATMENT, 2020-2029 (USD MILLION)
FIGURE 26 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 27 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 28 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY ROUTE OF AMINISTRATION, 2021
FIGURE 29 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 30 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY ROUTE OF AMINISTRATION, CAGR (2022-2029)
FIGURE 31 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY ROUTE OF AMINISTRATION, LIFELINE CURVE
FIGURE 32 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY END USERS, 2021
FIGURE 33 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY END USERS, 2020-2029 (USD MILLION)
FIGURE 34 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY END USERS, CAGR (2022-2029)
FIGURE 35 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY END USERS, LIFELINE CURVE
FIGURE 36 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 37 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 38 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 39 COLOMBIA GASTRIC CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 COLOMBIA GASTRIC CANCER DRUGS MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
